Market Place
Sourcing Support
Palvella Doses 1st Patient in SELVA Phase 3 for Lymphatic Malformations
07 Nov 2024 //
GLOBENEWSWIRE
Palvella Therapeutics Appoints Matthew Korenberg As CFO
17 Oct 2024 //
GLOBENEWSWIRE
Palvella Announces Presentations At PeDRA Annual Conference
15 Oct 2024 //
GLOBENEWSWIRE
Palvella Gets $2.6M FDA Grant For Lymphatic Malformation Trial
03 Oct 2024 //
GLOBENEWSWIRE
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership
01 Dec 2023 //
GLOBENEWSWIRE
Palvella Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN
16 Nov 2023 //
GLOBENEWSWIRE
Palvella Announces Phase 3 Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel
20 Jul 2023 //
GLOBENEWSWIRE
Palvella Announces Positive Topline Results from Phase 2 Study of QTORIN
09 Mar 2023 //
GLOBENEWSWIRE
Palvella Announces Pipeline Update on QTORINâ 3.9% Rapamycin Anhydrous Gel
21 Feb 2023 //
GLOBENEWSWIRE
Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million
05 Jan 2023 //
GLOBENEWSWIRE
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
28 May 2020 //
BUSINESSWIRE
Palvella`s Commences Ph3 Portion of Phase 2/3 Pivotal Study of PTX-022
13 Nov 2019 //
GLOBENEWSWIRE
MedPharm and Palvella expand pachyonychia congenita partnership
19 Feb 2019 //
THEPHARMALETTER
MedPharm & Palvella Expand Partnership
11 Feb 2019 //
CONTRACT PHARMA
Ligand Acquires Rights to PTX-022 from Palvella Therapeutics
18 Dec 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.